Suppr超能文献

玻璃体内注射阿柏西普治疗与年龄相关性黄斑变性相关的难治性色素上皮脱离伴或不伴视网膜下液。

OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.

机构信息

Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Republic of Korea.

Department of Ophthalmology, Seonam University Myongji Hospital, Goyang, Republic of Korea.

出版信息

Retina. 2019 Feb;39(2):303-313. doi: 10.1097/IAE.0000000000001947.

Abstract

PURPOSE

To investigate the outcomes of intravitreal aflibercept in refractory pigment epithelial detachment (PED) with or without subretinal fluid (SRF) in patients with neovascular age-related macular degeneration.

METHODS

A prospective, nonrandomized, interventional case series involved 40 patients with persistent vascularized PED previously treated with at least 3 injections of intravitreal bevacizumab or ranibizumab. Intravitreal aflibercept was administered as 3 initial loading doses every 4 weeks, followed by pro re nata retreatment every 8 weeks over 48 weeks. Pigment epithelial detachment was classified into solid-, hollow-, or mixed-type according to the reflective properties visualized using optical coherence tomography. The mean changes in best-corrected visual acuity, central subfield thickness, and the volumes of SRF and PED were analyzed.

RESULTS

The PED volume (baseline: 0.43 ± 0.55 mm) significantly reduced to 0.23 ± 0.32 mm at Week 8 (P = 0.003) and increased to 0.36 ± 0.41 mm at Week 48 (P = 0.345). The SRF volume (baseline: 0.52 ± 0.64 mm) significantly reduced to 0.24 ± 0.43 mm at Week 48 (P = 0.021). The mean baseline best-corrected visual acuity was 20/75 (47.5 letters); it showed no significant difference at Week 48 (+4.4 letters; P = 0.125). The baseline central subfield thickness was 323.2 ± 92.3 μm; it significantly reduced to 281.2 ± 90.7 μm at Week 48 (P = 0.001). In solid-type PEDs, there were poorer improvements in central subfield thickness, best-corrected visual acuity, and the volumes of the SRF and PED, with newly developed intraretinal cysts.

CONCLUSION

Intravitreal aflibercept in treatment-resistant neovascular age-related macular degeneration led to significant reduction in PED and SRF volume, central subfield thickness, and best-corrected visual acuity preserved, over 12 months. However, solid-type PED showed less improvement than hollow- or mixed-type PED.

摘要

目的

研究玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性伴或不伴脉络膜视网膜下积液(SRF)的难治性色素上皮脱离(PED)的结果。

方法

前瞻性、非随机、干预性病例系列研究纳入了 40 例先前接受过至少 3 次玻璃体内贝伐单抗或雷珠单抗治疗的持续性血管化 PED 患者。玻璃体内注射阿柏西普,每 4 周给予 3 次初始负荷剂量,然后在 48 周内每 8 周按需进行重复治疗。根据光学相干断层扫描(OCT)显示的反射特性,将色素上皮脱离分为实性、空洞性或混合性。分析最佳矫正视力、中央视网膜下厚度(中央凹下厚度)以及 SRF 和 PED 体积的平均变化。

结果

PED 体积(基线:0.43±0.55mm)在第 8 周时显著降低至 0.23±0.32mm(P=0.003),在第 48 周时增加至 0.36±0.41mm(P=0.345)。SRF 体积(基线:0.52±0.64mm)在第 48 周时显著降低至 0.24±0.43mm(P=0.021)。平均基线最佳矫正视力为 20/75(47.5 个字母);第 48 周时无显著差异(增加 4.4 个字母;P=0.125)。基线中央凹下厚度为 323.2±92.3μm;第 48 周时显著降低至 281.2±90.7μm(P=0.001)。在实性 PED 中,中央凹下厚度、最佳矫正视力、SRF 和 PED 体积的改善较差,同时出现新的视网膜内囊。

结论

玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性导致 PED 和 SRF 体积、中央凹下厚度和最佳矫正视力在 12 个月内显著减少。然而,实性 PED 的改善不如空洞性或混合性 PED。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验